- Home
- NEOV vs CLSD Comparison
NEOV vs CLSD Comparison
Compare NEOV & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- CLSD
- Stock Information
- Founded
- NEOV 2018
- CLSD 2011
- Country
- NEOV United States
- CLSD United States
- Employees
- NEOV N/A
- CLSD N/A
- Industry
- NEOV Industrial Machinery/Components
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- CLSD Health Care
- Exchange
- NEOV Nasdaq
- CLSD Nasdaq
- Market Cap
- NEOV 72.2M
- CLSD 68.4M
- IPO Year
- NEOV N/A
- CLSD 2016
- Fundamental
- Price
- NEOV $4.22
- CLSD $0.42
- Analyst Decision
- NEOV Strong Buy
- CLSD Hold
- Analyst Count
- NEOV 1
- CLSD 4
- Target Price
- NEOV $7.50
- CLSD $4.33
- AVG Volume (30 Days)
- NEOV 302.5K
- CLSD 12.9M
- Earning Date
- NEOV 09-26-2025
- CLSD 08-08-2025
- Dividend Yield
- NEOV N/A
- CLSD N/A
- EPS Growth
- NEOV N/A
- CLSD N/A
- EPS
- NEOV N/A
- CLSD N/A
- Revenue
- NEOV $4,255,136.00
- CLSD $4,166,000.00
- Revenue This Year
- NEOV $208.50
- CLSD $78.37
- Revenue Next Year
- NEOV $128.75
- CLSD $17.79
- P/E Ratio
- NEOV N/A
- CLSD N/A
- Revenue Growth
- NEOV 52.64
- CLSD N/A
- 52 Week Low
- NEOV $1.80
- CLSD $0.29
- 52 Week High
- NEOV $6.11
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- NEOV 45.99
- CLSD 39.95
- Support Level
- NEOV $3.55
- CLSD $0.40
- Resistance Level
- NEOV $5.38
- CLSD $0.47
- Average True Range (ATR)
- NEOV 0.51
- CLSD 0.06
- MACD
- NEOV -0.17
- CLSD 0.01
- Stochastic Oscillator
- NEOV 36.61
- CLSD 26.87
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.